 |
|
|
|
|
|
| |
|
| |
Fluofix is a fluorocarbonaceous, silane-bonded silica-gel phase for HPLC modfied with
"tridecafluoro-/4.4-Dimethylheptyl"silane
|
| |
|
|
|
|
|
| |
Advantages of Fluofix: |
1.) Group Separation of mixtures of basic and acidic compounds
2.) Precise separation of geometric isomers
3.)Iseparation of fluorinated or chlorinated compounds
4.) More stable than C4 or C8 phases |
|
| |
|
|
|
|
|
| |
|
| |
|
|
|
|
|
| |
 |
|
| |
Eluent:
MeOH/H20 (65/35)
Flow rate: 1ml/min.
Dimension:
150 x 4.6 mm
Temperature: 40 C°
Detection: 254 nm |
|
|
|
|
| |
|
|
|
|
|
| |
|
| |
|
|
|
|
|
| |
 |
|
| |
Fluofix 120 E, 5 µm
250 x 4.6 mm
Eluent:
MeOH/0,1% H3PO4
(14/86
ODS, 250 x 4.6 mm, 5 µm
Eluent:
MeOH/0,1%H3PO4 (29)
Flow rate: 1ml/min.
Detection: 254 nm |
|
|
|
|
| |
|
|
|
|
|
| |
|
| |
|
|
|
|
|
| |
 |
|
|
| |
|
|
|
|
|
| |
Column: Fluofix 120 E, 5 µm (250 x 4.6 mm)
Flow rate: 1 ml/min.
Gradient: A:water /85 % o-Phosphoric acid (99,5 /0,5 v/v)
B: ACN /Water / 85 % o-Phosphoric acid (99,5 / 0,5 v/v)
0-5 min.: 0 % B, 5-45 min.: to 25 % B, 45-64 min.: to 80 % B,
65-70 min.: to 100 %B, until 84,9 min. 100 % B.
Sample:
1=Gallic Acid, 2=Protocatechinic Acid,
3=Tyrosol, 4=(+Catechine,
5=Procyanindin B2,
6=Coffee Acid
7=Chlorogenic Acid, 8=(-)Epicatechine, 9=p-Cumaric Acid, 10=Ferulic Acid, 11=Quercetin-3-galactoside,
12=Quercetin-3-rutinoside, 13=Quercetin-3-glucoside,
14=Quercetin-3-arabinoside,
15=Phloridzin,
16=tr-Resveratrol,
17=Quercetin,
18=Kaempherol, 19=Phloretin |
|
|
|
| |
|
|
|
|
|
| |
|
| |
|
|
|
|
|
| |
Other Applications: Alkaloids, Androgenic Hormones, Angiotensin, Atropine, Benzurone, Barnon, Caffeine, Carotinoids, Carbamazepine, Catechins, Chlorfluazuron, Ciclopirox, Corticoids, Dibucaine, Diphenphydramine, Encephalins, Flavonoids, fatty Acids, unsaturated fatty Acids, Fluorbenzaldehyde, Follicle Hormone, Herbicides, Indole, Trichlorphenols, Lindocaine, Mataven, Nucleosids, Parabens, Phenols, Phentoin, Prostaglandines, Procainamide, Suffic, Tetracains, Theophylins, d-g-a-Tocopherols, Triton. |
|
| |
|
|
|
|
|
| |
|
| |
|
|
|
|
|
| |
back |
|
|
|
|
| |
|
|
|
|
 |
|
|
